Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids
Orihuela, P.A.
Current Opinion in Investigational Drugs 8(10): 859-866
2007
ISSN/ISBN: 1472-4472 PMID: 17907063 Document Number: 614475
HRA Pharma, under license from the Research Triangle Institute, is developing ulipristal, a progesterone receptor modulator, for the potential use as a contraceptive and an emergency contraceptive, and for the potential treatment of uterine fibroids. Phase II clinical trials for uterine fibroids and phase III trials for contraception are underway. The drug was expected to be launched in the US and Europe in 2009.